Glucovance

Glucovance is a prescription oral tablet that combines metformin hydrochloride and glibenclamide. It is classified as a biguanide/sulfonylurea combination and is marketed in the European Union. The product contains both agents in a fixed-dose formulation, though specific strength details are not disclosed here. Glucovance is intended for adult patients with type 2 diabetes mellitus to improve glycemic control. It is administered orally and requires a prescription from a healthcare professional.

Glucovance is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy with either component are insufficient.

- When metformin alone does not achieve target fasting glucose levels, Glucovance provides additional insulin secretagogue activity. - When sulfonylurea monotherapy fails to maintain post‑prandial glucose control, the metformin component adds hepatic glucose reduction. - Patients requiring a single tablet to simplify regimens may benefit from the fixed‑dose combination. - Glucovance can be used as part of a comprehensive diabetes care plan that includes diet, exercise, and regular monitoring. - The combination is appropriate for adults with preserved pancreatic beta‑cell function who need both insulin sensitization and stimulation.

Glucovance may be associated with adverse effects typical of its individual components; patients should be aware of both common and less frequent serious reactions.

Common: - Nausea, vomiting, or abdominal discomfort. - Diarrhea or loose stools. - Mild hypoglycemia, especially when meals are missed. - Headache or dizziness. - Metallic taste in the mouth. - Weight gain or loss, variable among patients.

Serious: - Lactic acidosis, a rare but life‑threatening condition. - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic dysfunction manifested by elevated liver enzymes. - Pancreatitis presenting with abdominal pain and elevated enzymes.

The frequency and severity of these events can vary based on individual health status and concomitant medications.

When prescribing Glucovance, clinicians should evaluate patient history and monitor for conditions that could increase risk of adverse outcomes.

- Avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to increased metformin accumulation. - Caution in moderate renal dysfunction; dose adjustment and monitoring are recommended. - Do not prescribe to individuals with known hypersensitivity to metformin, glibenclamide, or any sulfonylurea. - Use carefully in patients with hepatic disease, as reduced clearance may elevate drug levels. - Elderly patients may be more prone to hypoglycemia; begin with the lowest effective dose. - Pregnancy and lactation status should be reviewed; safety data are limited.

Glucovance can interact with several medications; recognizing these interactions helps to prevent reduced efficacy or increased toxicity.

Avoid: - Concurrent use with iodinated contrast media for radiographic studies; metformin should be discontinued before and after the procedure. - Other sulfonylureas or meglitinides, which may increase risk of severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glibenclamide plasma levels.

Use with caution: - Renal‑impairing agents such as ACE inhibitors or NSAIDs; monitor kidney function. - Corticosteroids or thiazide diuretics that may raise blood glucose; adjust dose as needed. - Alcohol consumption, which can potentiate metformin‑related lactic acidosis.